Montreal-based IntelGenx (OTCQX: IGXT), a leading Oral Drug Delivery technology company, uses a suite of proprietary technologies to provide its pharmaceutical partners with a range of superior and cutting-edge drug delivery solutions. The company’s underlying mission is to be the primary medical choice when it comes to oral solid dose innovation.

IntelGenx proprietary technologies include both film and tablet platforms:

VersaFilm™ enables the development of oral thin films for enhanced Oral Drug delivery, offering:

• Rapid disintegration without the need for water
• Quicker buccal or sublingual absorption
• Potential for faster onset of action and increased bioavailability
• Potential for reduced adverse effects by bypassing first-pass metabolism
• Easy administration for patients who have problems in swallowing: pediatric, geriatric, fear choking and/or suffering from nausea (e.g., nausea resulting from chemotherapy, radiotherapy or any surgical treatment)
• Pleasant taste
• Small and thin size, making it convenient for consumers
• Can be used for veterinary applications

VersaTab™ multilayer tablet technology offers a new level of controlled-release tablets:

• Linearization of the release profile using controlled erosion of inactive cover layers
• Reduction in peak plasma concentration reduces side effects
• Potential to deliver multiple actives with independent release profiles
• Separation of active ingredients to avoid chemical incompatibility
• Improved patient compliance due to reduced dosing frequency

AdVersa™ is a mucoadhesive tablet for controlled rate release of active ingredients:

• Fast mucosal absorption formulations for highly permeable drugs
• Improved bioavailability
• Avoid high drug metabolization
• Limited gastro-intestinal exposure
• Equal therapeutic effect achieved while reducing API loading
• Increased absorption of poorly soluble API
• Rapid or immediate release delivery
• Versatile residence time achieved to enhance/control absorption
• Targeted profile concentrations maintained
• Improved patient compliance

With these technologies, IntelGenx has developed a growing portfolio of products, including:

• Rizaport, the first rizatriptan oral disintegrating film for the treatment of migraine to achieve EU marketing approval
• Tadalafil, one of the three major PDE5 inhibitors in the erectile dysfunction market, a film-based product offering longer duration of action and less food effect, and improved discrete dosage form that does not require water intake
• Loxapine, an oral film for the treatment of anxiety and aggression in patients suffering from schizophrenia or bipolar 1 disorder
• Montelukast, for the treatment of degenerative diseases of the brain, such as mild cognitive impairment and Alzheimer’s disease, the most prominent form of dementia
• Forfivo XL® (Bupropion extended-release), the first 450 mg bupropion HCl tablet indicated for Major Depressive Disorder to be approved by the FDA
• INT0028, an improved product formulated using AdVersa™ containing dronabinol (THC) for the symptomatic management of neuropathic pain

In addition, IntelGenx has become a source of comprehensive pharmaceutical services to its partners, providing R&D, clinical monitoring, IP protection, analytical method development and regulatory services.

For more information on the company, visit www.IntelGenx.com